InnoCare’s TYK2 Performs Well in Phase II PsO Study
InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-488 met its primary endpoint in adults with moderate-to-severe plaque psoriasis in a phase II clinical study. ICP-488 is an oral TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of interleukin (IL)-23, IL-12, type 1 interferon (IFN) and other inflammatory cytokine, […]